Interleukin II (60-70)
(Synonyms: H2N-Leu-Thr-Phe-Lys-Phe-Tyr-Met-Pro-Lys-Lys-Ala-OH ) 目录号 : GP10029
Cytokine,regulating WBC
Cas No.:800379-41-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Interleukin II (60-70), (C68H104N14O14S), is a peptide with the sequence NH2- LEU-THR-PHE-LYS-PHE-TYR-MET-PRO-LYS-LYS-ALA-COOH, MW= 1373.7. Interleukin 2 (IL-2) is a type of cytokine signaling molecule in the immune system, and it regulates the activities of the white blood cells (leukocytes, often lymphocytes) responsible for immunity. IL-2, a soluble hormone-like mediator of the immune system, was the first interleukin molecule to be identified and characterized. IL-2 is necessary for the growth, proliferation, and differentiation of T cells to become 'effector' T cells. IL-2 is normally produced by T cells during an immune response. It is necessary for the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones.IL-2 is also necessary for the maturation of a subset of T cells, termed regulatory T cells, during T cell development in the thymus.
References:
1. Cantrell DA, Smith KA (June 1984). "The interleukin-2 T-cell system: a new cell growth model". Science 224 (4655): 1312-6.
2. Smith KA (May 1988). "Interleukin-2: inception, impact, and implications". Science 240 (4856): 1169-76.
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (August 1995). "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases". J. Immunol. 155 (3): 1151-64.
4. ThorntonAM, Shevach EM (July 1998). "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production". J. Exp. Med. 188 (2): 287-96.
| Cas No. | 800379-41-3 | SDF | |
| 别名 | H2N-Leu-Thr-Phe-Lys-Phe-Tyr-Met-Pro-Lys-Lys-Ala-OH | ||
| Canonical SMILES | N[C@@H](CC(C)C)C(N[C@H]([C@@H](C)O)C(N[C@H](CC1=CC=CC=C1)C(N[C@H](CCCCN)C(N[C@H](CC2=CC=CC=C2)C(N[C@H](CC3=CC=C(O)C=C3)C(N[C@H](CCSC)C(N4CCC[C@@H]4C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C68H104N14O14S1 | 分子量 | 1373.7 |
| 溶解度 | ≥ 137.3mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.728 mL | 3.6398 mL | 7.2796 mL |
| 5 mM | 0.1456 mL | 0.728 mL | 1.4559 mL |
| 10 mM | 0.0728 mL | 0.364 mL | 0.728 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet